Record Details

Palivizumab e virus respiratorio sinciziale: una panoramica

Farmeconomia

View Archive Info
 
 
Field Value
 
Title Palivizumab e virus respiratorio sinciziale: una panoramica
 
Creator Manzoni, Paolo
 
Subject Pharmacoeconomics; Health economics
Palivizumab; Respiratory Syncytial Virus; RSV prophylaxis
 
Description Respiratory Syncytial Virus (RSV) is a very frequent cause of respiratory infections in the first two years of life. Symptoms of­ten are mild to moderate, but in some high-risk categories of infants, particularly prematures and children with bronchopulmonary dysplasia or congenital heart disease, RSV can cause severe lower respiratory tract infections with need of hospitalisation, and, sometimes, even death. No effective treatment is available, and specific vaccines, despite several attempts during the last decades, do not exist. Palivizumab is a humanised monoclonal antibody targeting specific viral mechanisms controlling infection. If administered intramuscularly monthly during the RSV season as prophylaxis to high risk patients < 2 years of age, this antibody effectively reduces hospitalisation rates and severity of RSV infection. Based on the data from the two main phase III trials conducted so far, palivizumab prophylaxis results in 45% to 55% reduction of hospitalisation rate, with a very satisfactory profile of tolerability as most commonly reported adverse events where transient and mild irritability, diar­rhoea or fever.
 
Publisher SEEd Medical Publishers
 
Date 2011-07-15
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
—
 
Format application/pdf
 
Identifier https://journals.edizioniseed.it/index.php/FE/article/view/984
10.7175/fe.v12i3S.984
 
Source Farmeconomia. Health economics and therapeutic pathways; Vol 12, No 3S (2011); 3-16
2240-256X
 
Language eng
 
Relation https://journals.edizioniseed.it/index.php/FE/article/view/984/1202
 
Rights Copyright (c) 2011 Farmeconomia. Health economics and therapeutic pathways
http://creativecommons.org/licenses/by-nc/4.0